Evidence map›Paper›PMID 32170710›Full record

ReviewAging clinical and experimental research2020

Alternative and complementary therapies in osteoarthritis and cartilage repair.

N R Fuggle, C Cooper, R O C Oreffo, A J Price, J F Kaux, E Maheu, M Cutolo, G Honvo, P G Conaghan, F Berenbaum and 17 more

Open access · hybridAbstract readReview
In one paragraph

Review in Aging clinical and experimental research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 8 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 8 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. The effect of a multi-herbal product,Research in pharmaceutical sciences · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 12 countries.

N R FuggleMRC Lifecourse Epidemiology Unit, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK.
C CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK. cc@mrc.soton.ac.uk.ORCID http://orcid.org/0000-0003-3510-0709
R O C OreffoBone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton, UK.
A J PriceNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
J F KauxDepartment of Physical and Rehabilitation Medicine & Sports Traumatology, FIFA Medical Centre of Excellence, IOC Research Centre for Prevention of Injury and Protection of Athlete Health, FIMS Collaborative Center of Sports Medicine, University Hospital and University of Liège, Liege, Belgium.
E MaheuRheumatology Department, AP-HP, Saint-Antoine Hospital, 4 Blvd. Beaumarchais, Paris, France.
M CutoloResearch Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy.
G HonvoWHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium.
P G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK.
F BerenbaumDepartment of Rheumatology, Sorbonne Université, INSERM CRSA, AP-HP Saint-Antoine Hospital, Paris, France.
J BrancoCentro Hospitalar de Lisboa Ocidental- Hospital Egas Moniz, Lisbon, Portugal.
M L BrandiDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
B CortetDepartment of Rheumatology and EA 4490, Lille University Hospital, Lille, France.
N VeroneseNational Research Council, Neuroscience Institute, Aging Branch, Padua, Italy.
A A KurthDepartment of Orthopaedic Surgery, Themistocles Gluck Hospital, Ratingen, Germany.
R MatijevicFaculty of Medicine, Clinic for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
R RothInstitute of Outdoor Sports and Environmental Science, German Sport University, Cologne, Germany.
J P PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada.
J Martel-PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada.
M VlaskovskaMedical Faculty, Department of Pharmacology, Medical University Sofia, 2, Zdrave Str, 1431, Sofia, Bulgaria.
T ThomasDepartment of Rheumatology, Hôpital Nord, CHU de Saint-Etienne, Saint-Étienne, France.
W F LemsLocation VU Medical Center, Department of Rheumatology and Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
N Al-DaghriChair for Biomarkers Research, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
O BruyèreWHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium.
R RizzoliDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
J A KanisMary McKillop Health Institute, Australian Catholic University, Melbourne, Australia.
J Y ReginsterWHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium.
University of Liège · BEUniversité de Montréal · CAAustralian Catholic University · AUFachklinik 360° · DEGerman Sport University Cologne · DEHospital de Egas Moniz · PTInserm · FRKing Saud University · SAMedical University of Sofia · BGMRC Lifecourse Epidemiology Unit · GBNeuroscience Institute · ITNIHR Oxford Musculoskeletal Biomedical Research Centre · GBNuffield Orthopaedic Centre · GBSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FRUniversity Hospital of Geneva · CHUniversity of Florence · ITUniversity of Genoa · ITUniversity of Leeds · GBUniversity of Novi Sad · RS

Funding

Department of Health 10/33/04Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Medical Research Council MR/R015651/1
6 · The paper itself

Abstract

Osteoarthritis (OA) is the most common joint condition and, with a burgeoning ageing population, is due to increase in prevalence. Beyond conventional medical and surgical interventions, there are an increasing number of 'alternative' therapies. These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference (or completely excluded) from current OA guidelines. Thus, the aim of this review was to synthesize the current evidence regarding autologous chondrocyte implantation (ACI), mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP), vitamin D and other alternative therapies. The majority of studies were in knee OA or chondral defects. Matrix-assisted ACI has demonstrated exceedingly limited, symptomatic improvements in the treatment of cartilage defects of the knee and is not supported for the treatment of knee OA. There is some evidence to suggest symptomatic improvement with MSC injection in knee OA, with the suggestion of minimal structural improvement demonstrated on MRI and there are positive signals that PRP may also lead to symptomatic improvement, though variation in preparation makes inter-study comparison difficult. There is variability in findings with vitamin D supplementation in OA, and the only recommendation which can be made, at this time, is for replacement when vitamin D is deplete. Other alternative therapies reviewed have some evidence (though from small, poor-quality studies) to support improvement in symptoms and again there is often a wide variation in dosage and regimens. For all these therapeutic modalities, although controlled studies have been undertaken to evaluate effectiveness in OA, these have often been of small size, limited statistical power, uncertain blindness and using various methodologies. These deficiencies must leave the question as to whether they have been validated as effective therapies in OA (or chondral defects). The conclusions of this review are that all alternative interventions definitely require clinical trials with robust methodology, to assess their efficacy and safety in the treatment of OA beyond contextual and placebo effects.

Indexed as

Age FactorsChondrocytesComplementary TherapiesFemaleHumansMaleMesenchymal Stem Cell TransplantationOsteoarthritis, KneeTransplantation, AutologousTreatment OutcomeVitamin DVitaminsVitamin DVitaminsAlternativeCartilageHerbalOsteoarthritisTherapyTreatment

Identifiers

PMID32170710
PMCPMC7170824
OpenAlexW3011384097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.